文献速递脑血管病

房颤筛查与常规管理患者新发卒中的严重程度和病因及既往卒中的影响:LOOP随机临床试验的事后分析

Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke: A Post Hoc Analysis of the LOOP Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

该研究为LOOP随机临床试验的事后分析,纳入6004例70岁及以上无已知房颤但合并高血压、糖尿病、心衰或既往卒中的受试者,比较植入式循环记录仪筛查房颤与常规管理。中位随访65个月,筛查组与对照组缺血性卒中及严重卒中的风险比分别为0.76和0.69,均未达统计学显著;无既往卒中者中风险比分别为0.68和0.54,达到统计学显著。

要点

  • 植入式循环记录仪筛查房颤未显著降低缺血性或严重卒中风险。
  • 无既往卒中者中,筛查与缺血性卒中风险比0.68及严重卒中风险比0.54相关。
  • 有既往卒中者中未见筛查的显著获益。

核心结论

  • LOOP试验事后分析显示,植入式循环记录仪筛查房颤与常规管理相比未显著降低缺血性或严重卒中风险。
  • 探索性亚组分析提示,无既往卒中的受试者中筛查可能降低上述结局风险。

研究设计与样本

  • LOOP随机临床试验的事后分析,在丹麦4个中心于2014年1月31日至2016年5月17日通过信件招募受试者。
  • 纳入70岁及以上无已知房颤但合并高血压、糖尿病、心衰或既往卒中之一者,共6004例随机分组:对照组4503例(平均年龄74.7岁,男性2375例[52.7%]),植入式循环记录仪组1501例(平均年龄74.7岁,男性792例[52.8%])。
  • 干预为植入式循环记录仪筛查房颤,若检出房颤持续6分钟及以上则启动抗凝,对照组为常规管理。
  • 中位随访65个月(IQR 59-70个月),数据分析时间为2022年4月1日至5月31日。

主要发现

  • 对照组既往卒中史794/4503例(17.6%),植入式循环记录仪组262/1501例(17.5%)。
  • 随访期间房颤诊断:对照组550例(12%) vs 植入式循环记录仪组477例(32%),其中89%(910例)启动抗凝。
  • 卒中总计315例(5.2%):对照组249例(5.5%) vs 植入式循环记录仪组66例(4.4%),mRS中位评分2分(IQR 1-3),组间无差异。
  • 缺血性卒中272例(4.5%):对照组217例(4.8%) vs 植入式循环记录仪组55例(3.7%),风险比0.76(95%CI 0.57-1.03;P=0.07);严重卒中123例(2.0%):对照组100例(2.2%) vs 植入式循环记录仪组23例(1.5%),风险比0.69(95%CI 0.44-1.09;P=0.11)。
  • 无既往卒中者中,缺血性卒中风险比0.68(95%CI 0.48-0.97;P=0.04),严重卒中风险比0.54(95%CI 0.30-0.97;P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atrial fibrillation (AF) screening trials have failed to demonstrate a significant reduction in stroke risk. The impact on stroke severity and the importance of prior strokes are unknown. OBJECTIVE: To assess stroke characteristics in patients undergoing implantable loop recorder (ILR) screening for AF vs usual care and assess the importance of prior stroke. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Atrial Fibrillation Detected by Continuous Electrocardiogram Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-Risk Individuals (LOOP) randomized clinical trial. Persons 70 years or older without known AF but diagnosed with 1 or more of the following, hypertension, diabetes, heart failure, or prior stroke, were screened for inclusion. Four sites in Denmark recruited participants by letter between January 31, 2014, and May 17, 2016. The median (IQR) follow-up period was 65 (59-70) months. Data were analyzed from April 1 to May 31, 2022. INTERVENTIONS: ILR screening for AF and anticoagulation initiation if AF duration of 6 minutes or longer was detected (ILR group) vs usual care (control group). MAIN OUTCOMES AND MEASURES: Adjudicated stroke, classified according to the modified Rankin Scale (mRS) using a score of 3 or more as a cutoff for severe (disabling or lethal) stroke, and according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification for ischemic strokes. RESULTS: A total of 6205 individuals were screened for inclusion, and 6004 were randomized and included in the analysis; 4503 participants (75%; mean [SD] age, 74.7 [4.1] years; 2375 male [52.7%]) were assigned to the control group and 1501 participants (25%; mean [SD] age, 74.7 [4.1] years; 792 male [52.8%]) were assigned to the ILR group. A total of 794 of 4503 participants (17.6%) in the control group had a history of prior stroke compared with 262 of 1501 participants (17.5%) in the ILR group. During follow-up, AF was diagnosed in 1027 participants (control group, 550 [12%] vs ILR group, 477 [32%]), and anticoagulation was initiated in 89% of these (910). A total of 315 participants (5.2%) had a stroke (control group, 249 [5.5%] vs ILR group, 66 [4.4%]), and the median (IQR) mRS score was 2 (1-3) with no difference across the groups. A total of 272 participants (4.5%) had ischemic stroke (control group, 217 [4.8%] vs ILR group, 55 [3.7%]), and 123 (2.0%) had severe stroke (control group, 100 [2.2%] vs ILR group, 23 [1.5%]), and the hazard ratios comparing the control and ILR groups were 0.76 (95% CI, 0.57-1.03; P = .07) and 0.69 (95% CI, 0.44-1.09; P = .11), respectively. For participants without prior stroke, the hazard ratios were 0.68 (95% CI, 0.48-0.97; P = .04) and 0.54 (95% CI, 0.30-0.97; P = .04), respectively. CONCLUSIONS AND RELEVANCE: This post hoc analysis of the LOOP randomized clinical trial found that ILR screening for AF did not result in a significant decrease in ischemic or severe strokes compared with usual care. Exploratory subgroup analyses indicated a possible reduction of these outcomes among participants without prior stroke. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02036450.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Diederichsen SZ, Frederiksen KS, Xing LY, et al. Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke: A Post Hoc Analysis of the LOOP Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 36036546. doi:10.1001/jamaneurol.2022.3031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。